Toxicology Report

Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -

Nicoumalone (Acenocoumarol, Sintrom)

What is Nicoumalone (Acenocoumarol, Sintrom)?

CAS No: 152-72-7

Nicoumalone (Acenocoumarol, Sintrom) is a pharmacologically or chemically characterised molecule whose biological activity, physicochemical properties, and toxicological profile have been evaluated to establish its health-based exposure limits for pharmaceutical manufacturing. Its molecular structure—defined by NMR, IR, mass spectrometry, and elemental analysis—determines receptor binding, metabolic transformation pathways, and chemical reactivity relevant to both therapeutic utility and toxicological risk assessment. ADME parameters including oral bioavailability, plasma protein binding, volume of distribution, and metabolic clearance inform toxicokinetic modelling applied during PDE derivation.

Threshold of Toxicological Concern methodology provides a default PDE for Nicoumalone (Acenocoumarol, Sintrom) when conventional toxicological data are insufficient for NOAEL-based derivation. Cramer class assignment follows the decision-tree algorithm: Class I structures with simple chemistry lacking reactive functional groups carry a TTC of 1800

To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).

Request Your Assessment

Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.

View Inquiry List →
What's included:
Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
9,000+
Toxicological & Exposure
Assessment Reports Delivered
70+
Subject Matter Experts
across global operations
12
In-House Ex-Agency
Toxicologists
3
Certification Bodies:
ERT · UKRT · DABT

Assessment Methodology

Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.

EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)

Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.

PIC/S – Shared Facilities and Contamination Control Guidance

Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.

ICH Q9 – Quality Risk Management

Provides a structured methodology for risk identification, assessment, control, communication, and review.

ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)

Applied for compounds with potential mutagenic or genotoxic concerns.

Risk-Based Toxicological Assessment

Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.

Weight-of-Evidence (WoE) Approach

Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.

Report Preparation Process

Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.

01

Comprehensive Data Review

Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.

02

Scientific Evaluation

Identification of critical endpoints and selection of appropriate exposure limits.

03

PDE / HBEL Derivation

Transparent and scientifically justified calculations aligned with global toxicological principles.

04

Ex-Agency Expert Review (Our Differentiator)

Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.

05

Final Report Delivery

Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).

Why Masuu Global?

Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.

✓

Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.

✓

Inspection-ready reports — scientifically defensible and audit-prepared from day one.

✓

Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).

✓

Practical implementation recommendations that translate science into actionable contamination control.

✓

Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.

✓

Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.

Ready to request your assessment?

Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.

Frequently Asked Questions

The substance listed as Nicoumalone (Acenocoumarol, Sintrom) is a coumarin-type vitamin K antagonist used as an oral anticoagulant. Because anticoagulants act at low doses, occupational exposure and cross-contamination deserve careful evaluation. A toxicological assessment supports health-based exposure limits and handling controls in manufacturing.

A PDE or ADE sets a health-based limit on daily exposure to Nicoumalone (Acenocoumarol, Sintrom) from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.

Where human dose information is available, it can help identify the lowest doses linked to pharmacological or adverse effects. This may refine the selection of the critical effect and the uncertainty factors applied. Because dose data have limits, they are interpreted with other evidence and the reasoning is recorded.

Relevant evidence may include repeat-dose toxicity, reproductive and developmental toxicity, genotoxicity, carcinogenicity, and pharmacological activity where available. The critical effect is selected based on data quality and relevance. When data are limited, a documented, risk-based approach is used to address the gaps.

Active ingredients can produce effects at doses far below those that cause classical toxicity. In the assessment, anticoagulant activity can be reviewed with therapeutic and non-clinical findings to decide which effect should set the limit. This helps ensure the PDE or OEL reflects the most relevant concern for exposed people.

An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.

An OEB places Nicoumalone (Acenocoumarol, Sintrom) in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.

It can. Fine powders and dust-generating operations may raise inhalation concerns, while solutions or granulated material can change how exposure occurs and which controls are suitable. The assessment should therefore state the form considered, such as powder, solution or granulated material, and explain how it affects the exposure scenario and recommendations.

An assessment should be reviewed when new toxicological data become available, when the way the substance is used or handled changes, or when relevant guidance is updated. Periodic review keeps limits current and helps ensure that the documented rationale still reflects the best available science and the actual manufacturing situation.

The two limits answer different questions. A PDE protects patients from residual material carried into other medicines, while an OEL protects workers from exposure during operations. They draw on related toxicology data, but their routes, durations and assumptions differ, so one value should not be reused for the other without scientific justification.

Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.

Use the Request Your Assessment option on this page and add Nicoumalone (Acenocoumarol, Sintrom) to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.

Book a Demo